Key result
Angiotensin II receptor blockers demonstrate antihypertensive, metabolic, and organ-protective effects that can positively affect the course of coronary atherosclerosis in patients with stable ischemic heart disease.
Why the study?
Sartans have pleiotropic, antihypertensive, metabolic, and organ-protective effects that may positively affect coronary atherosclerosis and reduce total cardiovascular risk in ischemic heart disease.
Does angiotensin II receptor blockers improve clinical outcomes in patients with stable ischemic heart disease?
Does angiotensin II receptor blockers improve clinical outcomes in patients with stable ischemic heart disease?
Angiotensin II receptor blockers offer pleiotropic benefits including nephroprotection, metabolic improvements, and anti-inflammatory effects that may reduce total cardiovascular risk in patients with stable ischemic heart disease.
May support ARB consideration in stable IHD; hypothesis-generating and requires prospective trial confirmation.
Highlights . The review synthesizes the results of clinical studies on the use of sartans. This topic is highly relevant due to the antihypertensive, metabolic and organ-protective effect of sartans, which can positively affect the course of coronary atherosclerosis. Abstract . Angiotensin II receptor blockers (sartans) are widely used to treat cardiovascular diseases. This class of drugs has antihypertensive and metabolic effects and organ-protective capabilities. Currently, sartans are of high interest due to their pleiotropic effect: improved lipid metabolism, antidiabetogenic action, nephroprotection, and, as a result, reduced total cardiovascular risk. The article presents an overview of clinical data on the use of sartans in patients with ischemic heart disease, the mechanisms of organ-protective effects and prospects of using this class of drugs for total cardiovascular risk reduction. The following data sources were used: e-Library, ClinicalTrials.gov, PubMed, trialbulletin.com, smartpatients.com, BioPortfolio.com.
No takes yet. Share an insight, caveat, or question.
Кочергина et al. (2022) conducted a review in Stable ischemic heart disease. Angiotensin II receptor blockers (sartans) was evaluated. Angiotensin II receptor blockers demonstrate antihypertensive, metabolic, and organ-protective effects that can positively affect the course of coronary atherosclerosis in patients with stable ischemic heart disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: